Answers are grounded in this paper and cite their sources.
Polydeoxyribonucleotide (PDRN) is a low-molecular-weight DNA fragment mixture routinely isolated from salmonid tissue and used for regenerative applications. Putative mechanisms for conventional PDRN activity include adenosine A2A receptor signaling and nucleotide salvage. The present study extracted a plant‑derived PDRN from Brassica rapa (BR‑PDRN) using a modified cetyltrimethylammonium bromide (CTAB) protocol followed by controlled sonication. BR‑PDRN had an A260/A280 ratio of 1.95‑2.05 and a fragment distribution of 50‑1,000 bp. These measurements suggest low protein contamination and the intended fragment‑size range; however, they do not establish pharmaceutical‑ or clinical‑grade equivalence as A260/A230, residual CTAB/phenol, endotoxin or other process impurities were not measured. In NIH3T3 fibroblasts, both animal‑derived PDRN and BR‑PDRN (50 µg/ml) increased cell viability, as measured by the 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide assay, and enhanced scratch wound closure at 48 h compared with the untreated control. BR‑PDRN also increased VEGF, PDGFB, KGF and EGF mRNA. In HaCaT keratinocytes, both preparations increased the CCK‑8 signal and scratch‑wound closure, with BR‑PDRN showing a greater late‑phase CCK‑8 response under the assay conditions. In differentiated 3T3‑L1 adipocytes, both preparations attenuated adiponectin and leptin secretion. Overall, BR‑PDRN exhibits in vitro regenerative activity comparable to an animal‑derived comparator across directly compared assays. Further analytical characterization, dose‑response studies and in vivo wound models should be conducted before clinical translation.
No takes yet. Share an insight, caveat, or question.
Ju et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: